Intratumoral administration of STING-activating nanovaccine enhances T cell immunotherapy.
Xiaoyi JiangJian WangXichen ZhengZhida LiuXinyu ZhangYuwei LiJonathan WilhelmJun CaoGang HuangJinlan ZhangBaran SumerJayanthi LeaZhigang LuJinming GaoMin LuoPublished in: Journal for immunotherapy of cancer (2022)
Our results demonstrate that intratumoral administration of PC7A nanovaccine achieved stronger antitumor immunity and efficacy over subcutaneous injection. These data suggest intratumoral administration should be included in the therapeutic design in the clinical use of nanovaccine.